Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 2/20 | 0.37 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30714633 | 0.91 | SLC6A5 (0.41) | GABRA5HTR3AALDH1A1 | |
| SCHEMBL31539881 | 0.89 | HTR3A (0.34) | NPC1RAB9AHTR3AALDH1A1 | |
| SCHEMBL30714616 | 0.84 | NPC1 (0.40) | HPGDSNPC1RAB9AGABRA5HTR3A | |
| SCHEMBL30714661 | 0.82 | MMP3 (0.38) | CNR2ALDH1A1SCN9A | |
| SCHEMBL30714672 | 0.82 | RAB9A (0.43) | HPGDSNPC1RAB9AGABRA5HTR3A | |
| SCHEMBL26696031 | 0.81 | MCHR1 (0.37) | NPC1RAB9AALDH1A1 | |
| SCHEMBL26874831 | 0.81 | MCHR1 (0.38) | RAB9AALDH1A1 | |
| SCHEMBL30714626 | 0.81 | PARG (0.34) | NPC1RAB9AGABRA5ALDH1A1 | |
| SCHEMBL30714670 | 0.80 | MCHR1 (0.40) | NPC1RAB9AALDH1A1 | |
| SCHEMBL30714611 | 0.80 | PARG (0.36) | NPC1RAB9AALDH1A1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-12-11 | — | — | US | disclosed |
| EP-4499624-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023230540-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | TRPV3, TRPM2, TRPV1 | HPGDS 671/4885NPC1 349/4885RAB9A 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.